Comparative Pharmacology
Head-to-head clinical analysis: HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE versus PRO BANTHINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE versus PRO BANTHINE.
HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE vs PRO-BANTHINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is a mu-opioid receptor agonist; homatropine methylbromide is an anticholinergic that reduces gastrointestinal motility and secretions.
Propantheline is a muscarinic receptor antagonist that competitively blocks the action of acetylcholine at postganglionic parasympathetic effector sites, resulting in anticholinergic effects such as decreased gastrointestinal motility and secretion.
1 tablet (containing homatropine methylbromide 5 mg and hydrocodone bitartrate 5 mg) orally every 4 to 6 hours as needed for cough. Maximum 6 tablets per 24 hours.
15 mg orally three times daily before meals and 30 mg orally at bedtime.
None Documented
None Documented
Hydrocodone: Terminal elimination half-life 3.8-6.4 hours (mean ~4.5 h) in adults; prolonged in hepatic/renal impairment (up to 12-15 h). Homatropine methylbromide: Terminal half-life ~4-6 hours via quaternary structure limiting CNS penetration.
Terminal elimination half-life is approximately 9 hours (range 6-12 hours) in patients with normal renal function; prolonged in renal impairment, requiring dose adjustment.
Hydrocodone: Renal excretion of metabolites (hydromorphone, norhydrocodone) as glucuronide conjugates (~60%) and unchanged drug (<10%). Biliary/fecal elimination accounts for ~20-30%. Homatropine methylbromide: Predominantly fecal elimination via biliary excretion as unchanged quaternary ammonium compound (~70-80%); renal excretion of unchanged drug (~10-20%).
Renal excretion accounts for approximately 70% of elimination, with 30% as intact drug and 40% as inactive metabolites; biliary/fecal excretion contributes less than 5%.
Category D/X
Category C
Anticholinergic
Anticholinergic